SillaJen Past Earnings Performance
Past criteria checks 0/6
SillaJen has been growing earnings at an average annual rate of 42.4%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been declining at an average rate of 17% per year.
Key information
42.4%
Earnings growth rate
50.9%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -17.0% |
| Return on equity | -16.0% |
| Net Margin | -1,414.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How SillaJen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,657 | -23,438 | 22,397 | 0 |
| 31 Mar 24 | 3,445 | -21,906 | 22,839 | 0 |
| 31 Dec 23 | 3,940 | -20,369 | 21,783 | 0 |
| 30 Sep 23 | 6,091 | -21,643 | 22,320 | 0 |
| 30 Jun 23 | 6,737 | -22,375 | 23,200 | 0 |
| 31 Mar 23 | 5,277 | -22,172 | 23,171 | 0 |
| 31 Dec 22 | 5,013 | -24,593 | 24,732 | 0 |
| 30 Sep 22 | 4,052 | -24,360 | 27,000 | 0 |
| 30 Jun 22 | 1,688 | -23,359 | 23,077 | 0 |
| 31 Mar 22 | 555 | -16,767 | 20,763 | 0 |
| 31 Dec 21 | 254 | -15,656 | 19,493 | 0 |
| 30 Sep 21 | 1,032 | -13,027 | 16,825 | 0 |
| 30 Jun 21 | 1,175 | -22,536 | 20,377 | 0 |
| 31 Mar 21 | 1,700 | -42,099 | 28,486 | 0 |
| 31 Dec 20 | 1,670 | -47,825 | 34,603 | 0 |
| 30 Sep 20 | 1,742 | -54,748 | 42,960 | 0 |
| 30 Jun 20 | 2,291 | -55,708 | 54,965 | 0 |
| 31 Mar 20 | 7,703 | -108,422 | 58,186 | 0 |
| 31 Dec 19 | 9,069 | -113,200 | 64,217 | 0 |
| 30 Sep 19 | 9,351 | -112,928 | 61,393 | 0 |
| 30 Jun 19 | 10,962 | -114,644 | 60,775 | 0 |
| 31 Mar 19 | 7,093 | -57,464 | 63,699 | 0 |
| 31 Dec 18 | 7,712 | -56,236 | 63,452 | 0 |
| 30 Sep 18 | 8,771 | -61,575 | 67,414 | 0 |
| 30 Jun 18 | 7,543 | -53,954 | 59,170 | 0 |
| 31 Mar 18 | 7,315 | -59,416 | 58,743 | 0 |
| 31 Dec 17 | 6,865 | -57,021 | 53,757 | 0 |
| 30 Sep 17 | 5,690 | -79,992 | 53,858 | 0 |
| 30 Jun 17 | 6,236 | -84,857 | 55,972 | 0 |
| 31 Mar 17 | 5,568 | -77,093 | 51,008 | 0 |
| 31 Dec 16 | 5,292 | -74,038 | 48,436 | 0 |
| 30 Sep 16 | 5,806 | -52,003 | 41,842 | 0 |
| 30 Jun 16 | 4,065 | -47,387 | 34,806 | 0 |
| 31 Mar 16 | 3,126 | -51,703 | 26,536 | 0 |
| 31 Dec 15 | 1,810 | -55,854 | 22,214 | 0 |
| 30 Sep 15 | 1,099 | -28,736 | 20,007 | 0 |
| 30 Jun 15 | 1,616 | -26,485 | 17,746 | 0 |
| 31 Mar 15 | 2,021 | -33,501 | 10,081 | 6,174 |
| 31 Dec 14 | 2,086 | -2,478 | 14,949 | 0 |
Quality Earnings: A215600 is currently unprofitable.
Growing Profit Margin: A215600 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A215600 is unprofitable, but has reduced losses over the past 5 years at a rate of 42.4% per year.
Accelerating Growth: Unable to compare A215600's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A215600 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (6.1%).
Return on Equity
High ROE: A215600 has a negative Return on Equity (-15.97%), as it is currently unprofitable.